| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Gabapentin | FAERS: 4 | US FAERS | |
| 2 | Amiodarone | FAERS: 2 | US FAERS | |
| 3 | Aprotinin | FAERS: 2 | US FAERS | |
| 4 | Aspirin-oxycodone hydrochloride-oxycodone terephthalate combination | FAERS: 1 | US FAERS | |
| 5 | Digoxin | FAERS: 1 | US FAERS | |
| 6 | Enalapril | FAERS: 1 | US FAERS | |
| 7 | Erlotinib Hydrochloride | FAERS: 1 | US FAERS | |
| 8 | rofecoxib | FAERS: 1 | US FAERS | |
| 9 | valdecoxib | FAERS: 1 | US FAERS | |
| 10 | Bortezomib | OFFSIDES | ||
| 11 | Clobazam | OFFSIDES | ||
| 12 | Doxylamine | OFFSIDES | ||
| 13 | Ezetimibe | OFFSIDES | ||
| 14 | Succinylcholine | OFFSIDES | ||
| 15 | alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination | OFFSIDES | ||
| 16 | darifenacin | OFFSIDES |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120241
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.